Revenues (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				9 Months Ended
	Dec. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2019	Sep. 30, 2022	Sep. 30, 2021
Revenue
Revenue accounted for under Topic 606		$ 9,153	$ 8,862			$ 26,364	$ 19,634
Product revenue, net
Revenue
Revenue accounted for under Topic 606		8,643	7,858			24,363	14,928
Collaboration revenue
Revenue
Revenue accounted for under Topic 606		141	562			866	3,377
Collaboration revenue | Sinovant Sciences, LTD | License Agreement
Revenue
Revenue accounted for under Topic 606							2,200
Collaboration revenue | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606						900
Collaboration revenue | Merck & Co | License Agreement
Revenue
Revenue accounted for under Topic 606							1,200
Collaboration revenue - Upfront payment | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606	$ 3,000			$ 1,000	$ 5,000
Research premium and grant revenue
Revenue
Revenue accounted for under Topic 606		$ 369	$ 442			$ 1,135	$ 1,329